Cephalon, Barr settle Fentora dispute Nov 13, 2009
The deal doesn't affect the status of the separate Fentora patent lawsuits with Watson Pharmaceuticals Inc. and its units. If another generic version of Fentora reaches the U.S. market before October of 2018, Barr is allowed to launch its version. (Yahoo News -- Pharmaceutical Industry News)
Biotech firm opens pharmaceutical lab at Phoenix site Nov 6, 2009
Abraxis Biosciences built the lab, at the site formerly owned by Watson Pharmaceuticals on 51st Avenue, to serve as the firm's manufacturing site for its pipeline of pharmaceuticals. Founder and Chairman Dr. Patrick Soon-Shiong said his company sought out the Watson location for its available workforce and the region's growing emphasis on increasing its biosciences sector. (AZCentral -- Business)
Abraxis Biosciences dedicates its new lab in Phoenix Nov 5, 2009
Abraxis Biosciences built the new lab, located at the site formerly owned by Watson Pharmaceuticals on 51st Avenue, to serve as the firm's manufacturing site for its pipeline of pharmaceuticals. Founder and Chairman Dr. Patrick Soon-Shiong said his company sought out the Watson location for its available workforce and the region's growing emphasis on growing its biosciences sector. (AZCentral -- Business)
Watson 3Q profit falls 11 percent on taxes, costs Nov 5, 2009
MORRISTOWN, N.J. Drug developer Watson Pharmaceuticals Inc. said Wednesday its profit fell 11 percent in the third quarter as higher taxes and charges offset a revenue boost. Watson said profit declined to $63 million, or 55 cents per share, from $71. (Yahoo News -- Pharmaceutical Industry News)
Mepha Pharma will receive first round bids on 23 October Oct 21, 2009
He compared the Mepha valuation to that of generics firm, Arrow Group, which sold to Watson Pharmaceuticals for USD 1. 75bn in June. (FT.com -- Markets)
Retrial of Ala.'s drug overpricing lawsuit delayed Sep 23, 2009
The retrial of Alabama's prescription drug overpricing lawsuit against California-based Watson Pharmaceuticals has been delayed ... Watson Pharmaceuticals. (Yahoo News -- Pharmaceutical Industry News)
Watson Offering $850 Million in Notes Aug 19, 2009
Watson Pharmaceuticals offering $850 million in mix of senior notes ... Drug developer Watson Pharmaceuticals Inc. said Tuesday it is offering $850 million in a mix of senior notes. (ABC News -- Wire)
Watson Prices $850 Million of Senior Unsecured Notes Aug 19, 2009
Watson Pharmaceuticals, Inc. logo. (PRNewsFoto/Watson Pharmaceuticals, Inc.) CORONA, CA UNITED STATES ... MORRISTOWN, N.J., Aug. 18 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: ), a specialty pharmaceutical company, today announced the pricing of a debt offering of $450. (PR Newswire)
Moody's ups Bowne outlook to 'stable' on repayment Aug 19, 2009
Moody's Investors Service on Tuesday assigned a "junk" rating to Watson Pharmaceuticals Inc.'s $850 million offering of senior notes. Moody's gave a Ba1 rating to the sale of five- and 10-year notes. (Fresno Bee -- Business)
Admissions Tips From UC Irvine Aug 18, 2009
Some of the companies we've worked with in the past few years are Mazda (), the , Toyota (), Watson Pharmaceuticals (), and Wet Seal () to name just a few. Page. (BusinessWeek)
Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) Aug 12, 2009
Since then, consent orders have been entered and/or settlements now have been reached in the cases against Anchen Pharmaceuticals, Inc., Belcher Pharmaceuticals, Inc., Caraco Pharmaceutical Laboratories, Ltd., Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., GeoPharma, Inc., Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals, Ltd., Lupin Pharmaceuticals, Inc. and Lupin Ltd., Mylan Pharmaceuticals Inc., Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc.,... (PR Newswire)
Watson Announces Limited Recall Of Fentanyl Transdermal System Aug 8, 2009
Watson Pharmaceuticals, Inc. logo. (PRNewsFoto/Watson Pharmaceuticals, Inc.) CORONA, CA UNITED STATES ... MORRISTOWN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: ), a leading specialty pharmaceutical company, announced today that one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States is being voluntarily recalled from wholesalers and pharmacies. (PR Newswire)
Watson Pharmaceuticals and Arrow Group Receive FTC Second Request Aug 7, 2009
Watson Pharmaceuticals, Inc. logo. (PRNewsFoto/Watson Pharmaceuticals, Inc.) CORONA, CA UNITED STATES ... MORRISTOWN, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: ), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's pending acquisition of privately held Arrow Group. (PR Newswire)
Watson Pharma says FDA approved generic Toprol XL Aug 4, 2009
MORRISTOWN, N.J. Watson Pharmaceuticals Inc. said Monday it received approval for a generic version of the high blood pressure and angina drug Toprol XL, and plans to begin shipping the product immediately. Watson said the Food and Drug Administration approval 25 mg and 50 mg extended-release tablets of metoprolol. (Yahoo News -- Pharmaceutical Industry News)
Nasdaq Edges Higher While Others Slip Jul 29, 2009
Earnings Wednesday: Akamai Technologies (), ArcelorMittal (), Asiainfo (), Digital River (), Express Scripts (), Euronet (), General Dynamics (), Green Mountain Coffee Roasters (), Medco Health Solutions (), Moody's (), NetLogic Microsystems (), Nice Systems (), Oceaneering International (), Penn National Gaming (), Sprint Nextel (), Tetra Tech (), Visa (), Watson Pharmaceuticals (), and WellPoint (). Data on durable goods and the Fed's beige book will also be out Wednesday. (Investors Business Daily)
Watson Pharmaceuticals' CFO Takes Leave Jul 28, 2009
Watson Pharmaceuticals Inc. said Monday Chief Financial Officer Mark W. Durand has taken a leave of absence due to health reasons ... Shares of Watson Pharmaceuticals closed up 42 cents, or 1. (ABC News -- Wire)
Mistrial declared in Alabama drug pricing trial Jul 14, 2009
A judge has declared a mistrial after jurors were unable to reach a verdict in the trial of Alabama's prescription drug overpricing lawsuit against California-based Watson Pharmaceuticals. Montgomery County Circuit Judge Charles Price said Monday jurors appeared to be hopelessly deadlocked after more than seven hours of deliberations. (Yahoo News -- Pharmaceutical Industry News)
Experts Urge Stronger Limits for Some Pain Drugs Jul 2, 2009
If the agency decides against a recall, panelists said it should at least require a strong "black-box" warning on such combination products, also made by Watson Pharmaceuticals Inc and Covidien Plc's Mallinckrodt unit. "This is clearly the biggest cause of overdose problems," said panelist Dr. Marie Griffin, a preventive medicine professor at Vanderbilt University Medical Center. (MEDLINEplus)
Marcial: Generic Lipitor Prospects Spur Watson Pharma Jul 1, 2009
Watson Pharmaceuticals 52-week price ... That's been the experience in the past few days of Watson Pharmaceuticals (), whose stock jumped to a 52-week high of 33. (BusinessWeek)
Watson gets FDA approval for generic Plan B Jun 26, 2009
NEW YORK Watson Pharmaceuticals Inc. said Wednesday it recieved Food and Drug Administration approval for a generic version of Duramed Pharmaceuticals' Plan B emergency contraceptive ... Watson Pharmaceuticals Inc. (Yahoo News -- Pharmaceutical Industry News)
Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R) Jun 25, 2009
Watson Pharmaceuticals, Inc. logo. (PRNewsFoto/Watson Pharmaceuticals, Inc.) CORONA, CA UNITED STATES ... MORRISTOWN, N.J., June 24 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: ), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0. (PR Newswire)
Watson to go global with $1.75 billion Arrow buy Jun 20, 2009
NEW YORK (Reuters) Watson Pharmaceuticals Inc (WPI.N) said on Wednesday that it would buy privately held Arrow Group for 1 ... Morningstar analyst Brian Laegler said: "After adjusting for generic Lipitor, which is huge, they paid a fair price for it. "I'm neutral on the deal, but it's a step in the right direction," Laegler said. Watson will pay 1.05 billion in cash and issue about 16.9 million shares, worth 500 million. It will pay the remaining 200 million in the form of zero-coupon preferred... (Yahoo News -- Pharmaceutical Industry News)
Watson Pharma to Buy Arrow Group for $1.75B Jun 18, 2009
Watson Pharmaceuticals to buy private generic drug maker Arrow Group for $1 ... Watson Pharmaceuticals Inc. said Wednesday it will buy smaller generic drug maker Arrow Group for $1. (ABC News -- Wire)
Novartis's Sandoz Unit Is Sued by J&J Over Patent for Contraceptive Pill Jun 16, 2009
J&J has sued other companies over their plans to sell generic versions of the pill, including Watson Pharmaceuticals Inc.. In its application, Sandoz told the FDA that the patent was either invalid, not infringed or unenforceable. (Bloomberg -- Europe)
Abbott, Baxter settle Alabama Medicaid suit May 23, 2009
A lawsuit against Watson Pharmaceuticals is still expected to begin on that date in Montgomery County Circuit Court. What do you think. (Crain's Chicago Business)
Paladin Reports 2009 First Quarter Financial Results May 7, 2009
Paladin obtained the Canadian license for Trelstar from Watson Pharma Inc., a subsidiary of Watson Pharmaceuticals, Inc. (NYSE: - ) in May 2005. Paladin launched Trelstar 11. (CCNMatthews Press Releases)
Watson CEO compensation drops 50 percent Apr 2, 2009
NEW YORK Watson Pharmaceuticals Inc. President and Chief Executive Paul M. Bisaro's compensation fell by 50 percent in his first full year at the helm of the drug developer on a steep decline in stock compensation, according to an Associated Press analysis. In 2008, Bisaro received just under $4. (Yahoo News -- Pharmaceutical Industry News)
Watson Announces a Nationwide Voluntary Recall of Propafenone HCL Tablets Due to Oversized Tablets Mar 25, 2009
FOR IMMEDIATE RELEASE -- CORONA, CA March 23, 2009 Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that one lot of Propafenone HCL 225 mg Tablets sold in 100 count bottles in the United States is being voluntarily recalled to the consumer level as a precautionary measure. The lot is being recalled because some tablets may contain slightly higher levels of the active ingredient than specified. (U.S. Food and Drug Administration -- Alerts)
Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer Mar 17, 2009
From October 2000 to August 2004, Dr. Hamdy was a Senior Principal Scientist at Watson Pharmaceuticals where he participated in an ANDA for testosterone gel for the treatment of hypogonadism that was approved 2005. He also participated in multiple INDs in oncology and autoimmune diseases leading to successful phase I and phase II programs. (PR Newswire)
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium Mar 7, 2009
Watson Pharmaceuticals, Inc. logo ... March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: ), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R) (naproxen sodium) tablets ... About Watson Pharmaceuticals, Inc.. (PR Newswire)
FDA: India drug makers lied about test results Feb 26, 2009
India has become one of the worlds leading suppliers of generic drugs in recent years, with companies like Ranbaxy and Dr. Reddys Laboratory able to undercut prices from U.S. competitors like Watson Pharmaceuticals. Concerns about Ranbaxy have been growing since FDA inspectors first uncovered quality problems at one of its factories in 2006. (MSNBC -- Health)
FTC accuses firms of delaying generic drug launch Feb 9, 2009
-based Watson Pharmaceuticals; Woodcliff Lake, N.J.-based Par Pharmaceutical Co.; and privately held, Minneapolis-based Paddock Laboratories ... Watson Pharmaceuticals. (Yahoo News -- Pharmaceutical Industry News)
Lawmakers propose bill to stop generic drug delays Feb 9, 2009
It filed suit last week against Solvay SA, which had struck deals in 2006 with generic drug companies Watson Pharmaceuticals Inc, Par Pharmaceuticals and Paddock Laboratories to delay their production of a cheaper version of Solvay's testosterone-replacement therapy AndroGel ... Watson Pharmaceuticals Inc. (Yahoo News -- Pharmaceutical Industry News)
FTC critical of delay in generic drugs Feb 8, 2009
-based Watson Pharmaceuticals; Woodcliff Lake, N.J.-based Par Pharmaceutical Co.; and privately held, Minneapolis-based Paddock Laboratories. The lawsuit marks the second time in less than a year that the FTC has challenged so-called "pay to delay" settlements, in which branded drug companies reward their generic competitors for staying off the market. (Montana Standard, MT)
Consumers are more important than stuffing drug-company coffers Feb 8, 2009
In applications to the Food and Drug Administration, Watson Pharmaceuticals, Par Pharmaceuticals, and Paddock Laboratories argued that Solvay's patent wasn't valid and that, in any case, they could manufacture generic versions of AndroGel without infringing upon it. Needless to say, Solvay was dismayed by the threat to its $400 million revenue stream. (Daily Iowan, IA)
